• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Becton Dickinson (BDX) Moved And What Investors Are Watching

    Simply Wall St·09/26/2026 02:27:10
    语音播报

    Becton Dickinson (BDX) is back in focus after resolving a long running SEC case tied to past disclosures on its Alaris infusion pump, while also rolling out its BD Vmax 160 automation system at Fairview Health Services.

    At a share price of US$183.82, Becton Dickinson has climbed strongly in recent months, with a 90 day share price return of 17.89% and a 1 year total shareholder return of 29.88%. This is despite the year to date share price return being down 5.70%, suggesting recent momentum has picked up as investors weigh closure of the Alaris issue alongside new pharmacy automation deployments and leadership changes in its digital and information functions.

    Scan opportunities around Becton Dickinson by comparing this SEC-settlement rebound story with our hand-picked 31 resilient stocks with low risk scores that aim to balance upside potential with tighter risk profiles.

    The rebound in Becton Dickinson after the Alaris settlement and Fairview pharmacy rollout is clear. The key question now is whether that rerating has already captured most of the upside, or if the current valuation still leaves room ahead.

    Most Popular Narrative: 6% Undervalued

    Becton Dickinson's widely followed valuation work points to a fair value of about $195.67 versus the last close at $183.82. This frames the recent share price rebound as only part of the story rather than the full move.

    The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue). This is expected to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.

    See why 25 investors see Becton Dickinson as 6% undervalued.

    Result: Fair Value of $195.67 (UNDERVALUED)

    Still, Becton Dickinson faces real pressure from rising tariffs and trade friction, as well as potential disruption from separating its Biosciences and Diagnostic Solutions operations.

    Find out about the key risks to this Becton Dickinson narrative.

    Next Steps

    Mixed messages on Becton Dickinson so far, with both concerns and bright spots in play, so move quickly, review the full picture, and weigh up the 4 key rewards and 2 important warning signs.

    Looking for more Becton Dickinson investment ideas?

    Do not stop at Becton Dickinson alone. Use the Simply Wall St screener to quickly spot fresh candidates that fit the way you like to invest.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.